GLP-1 weight loss stalls: what the science says about plateaus

What did @simplybridget12 actually say?

She offered a crowd-sourced list of stall-breaking tactics from her GLP-1 community, including upping calories and carbs, switching injection sites, adding or removing exercise, drinking more water, increasing protein, stopping protein shakes, lowering carbs, trying intermittent fasting, and tracking calories. She defined a true plateau as "no weight loss, no inches loss for at least four to six weeks" and was upfront that she is "not a nutritionist, not a doctor, not nothing." The video is anecdote-forward and community-sourced, not a clinical protocol. That framing matters when evaluating what follows.

Does the science back this up?

Some of it, loosely. The plateau definition is reasonable, and several behavioral strategies have at least modest evidence. But the injection site rotation claim has no published clinical support, and the contradictory advice, eat more carbs OR eat fewer carbs, eat more protein OR stop protein shakes, reflects the real problem: there is no single validated intervention for GLP-1 weight stalls.

Weight plateaus during caloric restriction are well-documented. Rosenbaum et al. (2008, American Journal of Clinical Nutrition) showed that adaptive thermogenesis, the body lowering its metabolic rate in response to weight loss, is a genuine physiological phenomenon. This is likely a bigger driver of stalls than any single behavioral tweak. On exercise, a 2022 meta-analysis by Bellicha et al. in Obesity Reviews confirmed that resistance training preserves lean mass during weight loss, which supports the creator's mention of strength training. Protein adequacy also has a decent evidence base: Moon and Koh (2020, Nutrients) found higher protein intake supports satiety and body composition during energy restriction. The intermittent fasting suggestion is more mixed. A 2022 trial by Liu et al. in the New England Journal of Medicine found calorie restriction alone was not significantly inferior to time-restricted eating for weight loss, which tempers enthusiasm for IF as a special stall-breaker.

What did they get wrong (or right)?

The injection site rotation claim is the weakest link here. Semaglutide and tirzepatide pharmacokinetics are not meaningfully altered by rotating between approved subcutaneous sites, based on the prescribing information for Wegovy and Zepbound respectively. There is no peer-reviewed evidence that switching from abdomen to arm changes drug absorption enough to restart weight loss. This is community folklore, not pharmacology.

The contradictory dietary advice is also a problem, not because any single suggestion is dangerous, but because presenting "eat more carbs" and "eat fewer carbs" as equivalent solutions without context is genuinely confusing. It could lead someone to cycle through random changes without understanding why they're doing it.

What she got right: the four-to-six week definition of a true plateau is conservative and reasonable. Most clinical definitions of weight loss plateaus use a similar window. Her consistent disclaimer that this is personal experience, not medical advice, is appropriate. And recommending people talk to their medical provider at the end of the video is exactly the right call.

What should you actually know?

Weight stalls on GLP-1 medications are common and have real physiological explanations beyond willpower or habits. GLP-1 receptor agonists work partly by slowing gastric emptying and reducing appetite signaling, but the body's adaptive responses to weight loss, including changes in leptin, ghrelin, and resting metabolic rate, continue regardless. Aronne et al. (2021, Obesity) noted that combination therapy targeting multiple pathways, as tirzepatide does by also acting on GIP receptors, produces greater weight loss partly because it may partially offset some adaptive responses.

If you are on a GLP-1 medication and experiencing a stall, the most evidence-supported steps are: ensure adequate protein intake (at least 1.2 g per kg of body weight is a common clinical target), incorporate resistance training to preserve lean mass, and confirm you are actually in a caloric deficit using tracked data rather than estimates. A dose adjustment or medication reassessment by your prescriber may also be appropriate after a sustained plateau. No behavioral hack, including rotating injection sites, replaces that conversation.